Wall Street Zen Upgrades Oric Pharmaceuticals Stock

Analysts raise rating on biotech firm's shares from 'sell' to 'hold'

Published on Mar. 3, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen, a research firm, has upgraded its rating on shares of Oric Pharmaceuticals (NASDAQ:ORIC) from 'sell' to 'hold' in a new report. The upgrade comes as several other analysts have also weighed in on the biotech company, with some maintaining 'outperform' ratings and price targets as high as $25 per share.

Why it matters

Oric Pharmaceuticals is a clinical-stage biotech focused on developing cancer treatments to overcome drug resistance. The company's lead candidate, ORIC-101, is currently in Phase 1/2 trials. Analyst sentiment and ratings can significantly impact a biotech stock's performance, so this upgrade from a 'sell' to 'hold' rating could provide a boost to Oric's share price.

The details

In its research report, Wall Street Zen cited Oric's progress in advancing ORIC-101 through clinical trials as a key factor behind the rating upgrade. Other analysts, including those from Oppenheimer, Piper Sandler, and HC Wainwright, have also weighed in on Oric, with some maintaining 'outperform' ratings and price targets as high as $25 per share.

  • Wall Street Zen upgraded Oric Pharmaceuticals shares on Saturday, March 3, 2026.

The players

Wall Street Zen

A research firm that covers the biotech and pharmaceutical industries.

Oric Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing cancer treatments to overcome drug resistance.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This upgrade from Wall Street Zen highlights the growing optimism around Oric Pharmaceuticals' pipeline and its lead drug candidate ORIC-101. As the company continues to advance its clinical trials, further positive news and analyst sentiment could provide a boost to the stock price.